Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Swiss approval for Rasilez HCT

This article was originally published in Scrip

Executive Summary

Novartishas received Swiss approval for Rasilez HCT, a single pill combination of its direct renin inhibitor aliskiren and the diuretic hydrochlorothiazide, for the treatment of hypertension. The combination was first approved in the US as Tekturna HCT in January (Scrip Online, January 21st, 2008) and is also awaiting approval in the EU (expected early next year) and many other markets. Aliskiren has been available as a single agent for treating high blood pressure as a monotherapy or in combination with other antihypertensive drugs since 2007. Many patients require two or more therapies to reach their treatment goals, and the new product should help reduce the pill burden.

You may also be interested in...



mRNA Vaccines – Trials Line Up Against Coronavirus

The arrival of SARS-CoV-2 has focused attention on a potential new way of making vaccines – one that promises to be quicker and cheaper than traditional methods and more reactive to novel virus outbreaks, but also one that remains to be validated.

Novartis Close To EU Approval For Zolgensma At Last

Novartis’s AveXis unit has received a CHMP nod for the spinal muscular atrophy gene therapy at its latest meeting, sending it on the final steps to market in the EU.

mRNA Vaccines – A Novel Weapon Against Coronavirus

The arrival of SARS-CoV-2 has focused attention on a potential new way of making vaccines – one that promises to be quicker and cheaper than traditional methods and more reactive to novel virus outbreaks, but also one that remains to be validated.

Topics

UsernamePublicRestriction

Register

SC030482

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel